BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 90 filers reported holding BELLICUM PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.40 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,000 | +20.0% | 5,000 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | -58.3% | 5,000 | -23.2% | 0.00% | – |
| Q2 2019 | $12,000 | +140.0% | 6,509 | +331.3% | 0.00% | – |
| Q1 2019 | $5,000 | 0.0% | 1,509 | -24.9% | 0.00% | – |
| Q4 2018 | $5,000 | -82.8% | 2,009 | -57.6% | 0.00% | – |
| Q3 2018 | $29,000 | -67.4% | 4,735 | -60.7% | 0.00% | – |
| Q2 2018 | $89,000 | +89.4% | 12,058 | +66.0% | 0.00% | – |
| Q1 2018 | $47,000 | +38.2% | 7,262 | +79.0% | 0.00% | – |
| Q4 2017 | $34,000 | -22.7% | 4,058 | +5.0% | 0.00% | – |
| Q3 2017 | $44,000 | +131.6% | 3,866 | +135.7% | 0.00% | – |
| Q2 2017 | $19,000 | -32.1% | 1,640 | -25.6% | 0.00% | – |
| Q1 2017 | $28,000 | – | 2,204 | +10920.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 20 | -89.9% | 0.00% | – |
| Q3 2016 | $4,000 | -85.2% | 198 | -89.1% | 0.00% | – |
| Q3 2015 | $27,000 | +145.5% | 1,823 | +261.0% | 0.00% | – |
| Q2 2015 | $11,000 | +120.0% | 505 | +151.2% | 0.00% | – |
| Q1 2015 | $5,000 | – | 201 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 1,051,441 | $3,070,000 | 0.79% |
| X-Square Capital, LLC | 109,832 | $321,000 | 0.25% |
| KNOTT DAVID M | 111,427 | $325,000 | 0.15% |
| ARK Investment Management | 1,033,491 | $3,018,000 | 0.12% |
| Baker Brothers Advisors | 2,677,818 | $7,819,000 | 0.06% |
| HARVEY CAPITAL MANAGEMENT INC | 31,200 | $91,000 | 0.05% |
| DAFNA Capital Management LLC | 30,000 | $88,000 | 0.04% |
| WASATCH ADVISORS LP | 953,368 | $2,784,000 | 0.04% |
| FRANKLIN STREET ADVISORS INC /NC | 51,415 | $150,000 | 0.02% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,000,000 | $2,920,000 | 0.02% |